Trial Profile
Phase I trial of CB 008 in patients with Ebola virus infections in West Africa
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 22 Jan 2015
Price :
$35
*
At a glance
- Drugs CB 008 (Primary)
- Indications Ebola virus infections
- Focus Adverse reactions
- Sponsors Canopus BioPharma
- 22 Jan 2015 New trial record
- 19 Dec 2014 This trial in West Africa is expected to be initiated after an Ebola study in primates, according to a Canopus BioPharma media release.